抗体偶联药物治疗转移性尿路上皮癌的临床研究进展

Advances in antibody-drug conjugates in the treatment of urothelial carcinoma

抗体偶联药物(ADC)是目前新型肿瘤药物研发的热点,同时具有抗体药物选择性强和化疗药物活性高的特点,目前已在多种实体瘤中得到广泛应用。全球范围内已有3种ADC药物获批治疗尿路上皮癌,包括恩诺单抗(Nectin-4抗体-MMAE偶联物)、戈沙妥珠单抗(Trop-2抗体-SN-38偶联物)和维迪西妥单抗(HER2抗体-MMAE偶联物),显著改善了晚期患者的预后,改变了尿路上皮癌的治疗模式。此外,一些ADC药物与靶向治疗、免疫检查点抑制剂联合应用的临床研究也正在开展。本文总结近年来ADC药物应用于尿路上皮癌治疗的临床研究进展。

At present,antibody-drug conjugate is the focus of the research and development of new anticancer drugs.Three antibody-drug conjugates have been approved for the treatment of urothelial carcinoma,including Enfortumab Vedotin(Nectin-4 antibody-MMAE conjugate),Sacitumab Govitecan(Trop-2 antibody-SN-38 conjugate),and Disitamab Vedotin(HER2 antibody-MMAE conjugate)significantly improved the prognosis in patients with advanced disease,revolutionizing the treatment landscape of urothelial carcinoma.In addition,a number of studies that focus on combination of antibody-drug conjugate with targeted therapy,immunocheckpoint inhibitors is also under way.This article reviews the recent clinical development of antibody-drug conjugate in the treatment of urothelial carcinoma in recent years.